LXRepair filed a patent application based on the analysis of melanoma samples using its SPOT-LX™ platform to generate DNA Repair profiles from tumors. The patent application outlines a method for stratifying patients, identifying DNA Repair defects and choose the best therapeutic option notably between targeted therapy and immunotherapy. LXRepair will continue its clinical research on melanoma to eventually develop a diagnostic test MELX™.